Eagle Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $242.71 million
- Book Value:
- Revenue TTM:
- $267.04 million
- Operating Margin TTM:
- Gross Profit TTM:
- $221.67 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Eagle Pharmaceuticals Inc had its IPO on 2014-02-12 under the ticker symbol EGRX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Eagle Pharmaceuticals Inc has a staff strength of 134 employees.
Shares of Eagle Pharmaceuticals Inc opened at $15.74 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.74 - $16.36, and closed at $16.29.
This is a +2.91% increase from the previous day's closing price.
A total volume of 99,105 shares were traded at the close of the day’s session.
In the last one week, shares of Eagle Pharmaceuticals Inc have slipped by -8.53%.
Eagle Pharmaceuticals Inc's Key Ratios
Eagle Pharmaceuticals Inc has a market cap of $242.71 million, indicating a price to book ratio of 1.724 and a price to sales ratio of 1.2927.
In the last 12-months Eagle Pharmaceuticals Inc’s revenue was $267.04 million with a gross profit of $221.67 million and an EBITDA of $69.08 million. The EBITDA ratio measures Eagle Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eagle Pharmaceuticals Inc’s operating margin was 19.62% while its return on assets stood at 8.92% with a return of equity of -1.16%.
In Q1, Eagle Pharmaceuticals Inc’s quarterly earnings growth was a negative -87.1% while revenue growth was a negative 42.8%.
Eagle Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.28 per share while it has a forward price to earnings multiple of 11.3379 and a PEG multiple of 0.91. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eagle Pharmaceuticals Inc’s profitability.
Eagle Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.5055 and a EV to EBITDA ratio of 7.5687. Its price to sales ratio in the trailing 12-months stood at 1.2927.
Eagle Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $414.18 million
- Total Liabilities
- $97.81 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Eagle Pharmaceuticals Inc ended 2023 with $414.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $414.18 million while shareholder equity stood at $242.85 million.
Eagle Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $97.81 million in other current liabilities, 18000.00 in common stock, $117.25 million in retained earnings and $45.03 million in goodwill. Its cash balance stood at $21.90 million and cash and short-term investments were $21.90 million. The company’s total short-term debt was $7,500,000 while long-term debt stood at $68.83 million.
Eagle Pharmaceuticals Inc’s total current assets stands at $192.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $114.95 million compared to accounts payable of $17.11 million and inventory worth $44.14 million.
In 2023, Eagle Pharmaceuticals Inc's operating cash flow was $-12558000.00 while its capital expenditure stood at $58000.
Comparatively, Eagle Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Eagle Pharmaceuticals Inc stock is currently trading at $16.29 per share. It touched a 52-week high of $47.71 and a 52-week low of $47.71. Analysts tracking the stock have a 12-month average target price of $29.5.
Its 50-day moving average was $18.53 and 200-day moving average was $25.33 The short ratio stood at 6.35 indicating a short percent outstanding of 0%.
Around 1309.9% of the company’s stock are held by insiders while 8956.8% are held by institutions.
Frequently Asked Questions About Eagle Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.